Baseline characteristics and dosing for patients treated in dasatinib trials in chronic-phase CML who had a mutational assessment performed at baseline
| . | Total, n = 1043 . | Imatinib resistant, n = 805 . | Imatinib intolerant, n = 238 . |
|---|---|---|---|
| Male, no. (%) | 516 (49) | 429 (53) | 87 (37) |
| Median age, y (range) | 56 (18-85) | 55 (18-85) | 57 (19-84) |
| Median duration of CML, mo (range) | 58 (1-251) | 68 (3-251) | 24 (1-183) |
| Highest imatinib dose, no. (%) | |||
| Less than 400 mg/day | 1 (< 1) | 1 (< 1) | 0 (0) |
| 400 to 600 mg/day | 643 (62) | 422 (52) | 221 (93) |
| More than 600 mg/day | 398 (38) | 382 (48) | 16 (7) |
| Prior imatinib treatment, % | |||
| Less than 1 y | 213 (20) | 72 (9) | 141 (59) |
| 1 to 3 y | 356 (34) | 291 (36) | 65 (27) |
| More than 3 y | 473 (45) | 442 (55) | 31 (13) |
| Other prior therapy, no. (%) | |||
| Interferon-α | 614 (59) | 508 (63) | 106 (45) |
| Stem cell transplantation | 72 (7) | 62 (8) | 10 (4) |
| Response achieved prior to imatinib failure, no. (%) | |||
| CHR | 882 (85) | 709 (88) | 173 (73) |
| MCyR | 387 (37) | 289 (36) | 98 (41) |
| CCyR | 192 (18) | 135 (17) | 57 (24) |
| Baseline BCR-ABL mutation, no. (%) | |||
| Yes | 402 (39) | 384 (48) | 18 (8) |
| No | 641 (61) | 421 (52) | 220 (92) |
| Dasatinib dose received, no. (%) | |||
| 100 mg QD | 147 (14) | 112 (14) | 35 (15) |
| 70 mg BID | 608 (58) | 475 (59) | 133 (56) |
| 140 mg QD | 139 (13) | 105 (13) | 34 (14) |
| 50 mg BID | 149 (14) | 113 (14) | 36 (15) |
| . | Total, n = 1043 . | Imatinib resistant, n = 805 . | Imatinib intolerant, n = 238 . |
|---|---|---|---|
| Male, no. (%) | 516 (49) | 429 (53) | 87 (37) |
| Median age, y (range) | 56 (18-85) | 55 (18-85) | 57 (19-84) |
| Median duration of CML, mo (range) | 58 (1-251) | 68 (3-251) | 24 (1-183) |
| Highest imatinib dose, no. (%) | |||
| Less than 400 mg/day | 1 (< 1) | 1 (< 1) | 0 (0) |
| 400 to 600 mg/day | 643 (62) | 422 (52) | 221 (93) |
| More than 600 mg/day | 398 (38) | 382 (48) | 16 (7) |
| Prior imatinib treatment, % | |||
| Less than 1 y | 213 (20) | 72 (9) | 141 (59) |
| 1 to 3 y | 356 (34) | 291 (36) | 65 (27) |
| More than 3 y | 473 (45) | 442 (55) | 31 (13) |
| Other prior therapy, no. (%) | |||
| Interferon-α | 614 (59) | 508 (63) | 106 (45) |
| Stem cell transplantation | 72 (7) | 62 (8) | 10 (4) |
| Response achieved prior to imatinib failure, no. (%) | |||
| CHR | 882 (85) | 709 (88) | 173 (73) |
| MCyR | 387 (37) | 289 (36) | 98 (41) |
| CCyR | 192 (18) | 135 (17) | 57 (24) |
| Baseline BCR-ABL mutation, no. (%) | |||
| Yes | 402 (39) | 384 (48) | 18 (8) |
| No | 641 (61) | 421 (52) | 220 (92) |
| Dasatinib dose received, no. (%) | |||
| 100 mg QD | 147 (14) | 112 (14) | 35 (15) |
| 70 mg BID | 608 (58) | 475 (59) | 133 (56) |
| 140 mg QD | 139 (13) | 105 (13) | 34 (14) |
| 50 mg BID | 149 (14) | 113 (14) | 36 (15) |
CML indicates chronic myeloid leukemia; CHR, complete hematologic response; MCyR, major cytogenetic response; CCyR, complete cytogenetic response; BID, twice daily; and QD, once daily.